MicroRNA-204 may predict the renal function in patients with chronic kidney disease
Medicine (United States), ISSN: 1536-5964, Vol: 104, Issue: 1, Page: e41202-null
2025
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Background: Chronic kidney disease significantly affects human health by loss of excretory kidney function. MicroRNAs have potential predictive and therapeutic significance for chronic kidney disease and fibrosis-related kidney diseases. This study aimed to investigate expression profiling and clinical significance of microRNA-204 (miR-204) expression in patients with chronic kidney disease. Methods: A total of 126 patients with chronic kidney disease and age-matched 126 healthy controls were enrolled in this study. Blood samples were collected from participants and expression levels of miR-204 were detected using reverse transcription quantitative polymerase chain reaction. Expression of inflammatory cytokines in glomerular cells was measured using reverse transcription quantitative polymerase chain reaction. Inflammatory cytokines in serum were analyzed using enzyme-linked immunosorbent assay in all participants. Multivariate Cox-regression analysis was used to analyze the association between serum level of miR-204 and inflammation, renal fibrosis, and degree of chronic kidney disease. Results: Chronic kidney disease patients had higher inflammatory cytokines including IL-1β, IL-6, TNF-α, IL-10, and IL-17 than healthy volunteers. Expression levels of inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-10, and IL-17) were upregulated in patients with chronic kidney disease compared to healthy volunteers. Serum level of miR-204 was lower in chronic kidney disease patients than healthy patients. Expression of miR-204 was higher in healthy volunteers than patients with chronic kidney disease. In addition, expression of miR-204 was lower in glomerular cells in chronic kidney disease patients than those in the healthy volunteers. Furthermore, higher serum level of miR-204 was associated with better renal function in chronic kidney disease patients than patients who had lower serum level of miR-204. High serum levels of miR-204 were associated with degree of renal fibrosis and injury of chronic kidney disease patients. Multivariate Cox-regression analysis identified expression of miR-204 was positively correlated with inflammation in patients with chronic kidney disease. Conclusion: Outcomes indicate that serum levels of miR-204 are downregulated in serum in patients with chronic kidney disease. Data suggest that serum levels of miR-204 can be used to evaluate the renal function in patients with chronic kidney diseasecopy; 2025 the Author(s). Published by Wolters Kluwer Health, Inc.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know